ARTICLE | Strategy

Momenta moving on

Why Momenta abandoning complex generics in favor of novel drugs and biosimilars

December 15, 2014 8:00 AM UTC

Data announced in October represent the first fruits of Momenta Pharmaceuticals Inc.'s novel drug pipeline, which will play a larger role in the company's strategy going forward as it steps back from complex generics.

Momenta was founded in 2001 to develop a platform technology to analyze complex carbohydrate molecules that are beyond the reach of conventional methods of characterization. By using the technology to solve what had been scientifically intractable problems, the company hoped to build a portfolio of complex generics, novel drugs and biosimilars - all of which would be insulated from competition by either IP or know-how created by the platform...